All In Biotech

Drug Trial Radar · NCT04626479

Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)

A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03A in First Line Metastatic Participants

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 393 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

393

Actual

Start

Dec 16, 2020

Primary completion

Aug 10, 2026

Study completion Aug 10, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Substudy 03A is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03A is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with advanced first line (1L) clear cell renal cell carcinoma (ccRCC). This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study.

Conditions

  • Carcinoma, Renal Cell

Interventions

  • PembrolizumabBiological

    Administered via IV infusion at a dose of 400 mg Q6W

  • Favezelimab/PembrolizumabBiological

    Administered via IV infusion at a dose of 800 mg/200 mg Q3W

  • BelzutifanDrug

    Administered via oral tablet at a dose of 120 mg QD

  • LenvatinibDrug

    Administered via oral capsule at a dose of 20 mg QD

  • Pembrolizumab/QuavonlimabBiological

    Administered via IV infusion at a dose of 400 mg/25 mg Q6W

  • Vibostolimab/PembrolizumabDrug

    Administered via IV infusion at a dose of 200 mg/200 mg Q6W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)Time frame: Up to ~21 days
  2. Safety Lead-in Phase: Number of participants who experience one or more adverse events (AEs)Time frame: Up to ~21 days
  3. Safety Lead-in Phase: Number of participants who discontinue study treatment due to an AETime frame: Up to ~21 days
  4. Efficacy Phase: Number of participants who experience one or more DLTsTime frame: Up to ~21 days
  5. Efficacy Phase: Number of participants who experience one or more AEsTime frame: Up to ~43 months
  6. Efficacy Phase: Number of participants who discontinue study treatment due to an AETime frame: Up to ~43 months
  7. Efficacy Phase: Objective response rate (ORR)Time frame: Up to ~43 months

Locations

55 sites in 14 countries. Site status is shown where the registry gives one.

  • University of California at San Francisco ( Site 1008)

    San Francisco, California

  • Yale-New Haven Hospital-Yale Cancer Center ( Site 1011)

    New Haven, Connecticut

  • University of Chicago ( Site 1013)

    Chicago, Illinois

  • University of Iowa ( Site 1012)

    Iowa City, Iowa

  • Henry Ford Health System ( Site 1014)

    Detroit, Michigan

  • Laura and Isaac Perlmutter Cancer Center ( Site 1016)

    New York, New York

  • Memorial Sloan Kettering Cancer Center ( Site 1002)

    New York, New York

  • Duke Cancer Institute ( Site 1015)

    Durham, North Carolina

  • UPMC Cancer Center/Hillman Cancer Center ( Site 1017)

    Pittsburgh, Pennsylvania

  • UTSW Medical Center ( Site 1003)

    Dallas, Texas

  • Blacktown Hospital ( Site 1601)

    Blacktown, New South Wales, Australia

  • St George Hospital ( Site 1602)

    Kogarah, New South Wales, Australia

  • Royal Brisbane and Women's Hospital ( Site 1603)

    Herston, Queensland, Australia

  • Austin Health ( Site 1600)

    Heidelberg, Victoria, Australia

  • Princess Margaret Cancer Centre ( Site 1101)

    Toronto, Ontario, Canada

  • Jewish General Hospital ( Site 1100)

    Montreal, Quebec, Canada

  • James Lind Centro de Investigacion del Cancer ( Site 2108)

    Temuco, Araucania, Chile

  • CIDO SpA-Oncology ( Site 2106)

    Temuco, Araucania, Chile

  • FALP-UIDO ( Site 2100)

    Santiago, Region M. de Santiago, Chile

  • Oncovida ( Site 2107)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill-Clinical Area ( Site 2101)

    Santiago, Region M. de Santiago, Chile

  • ONCOCENTRO APYS-ACEREY ( Site 2103)

    Viña del Mar, Valparaiso, Chile

  • Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 1900)

    Bogotá, Bogota D.C., Colombia

  • Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 1905)

    Valledupar, Cesar Department, Colombia

  • Instituto Médico de Alta Tecnologia S.A.S ( Site 1904)

    Montería, Departamento de Córdoba, Colombia

  • Fundación Valle del Lili ( Site 1901)

    Cali, Valle del Cauca Department, Colombia

  • Institut De Cancerologie De Lorraine ( Site 1204)

    Vandœuvre-lès-Nancy, Ain, France

  • C.H.U. de Strasbourg Hopital de Hautepierre ( Site 1203)

    Strasbourg, Bas-Rhin, France

  • Institut Claudius Regaud ( Site 1200)

    Toulouse, Haute-Garonne, France

  • Gustave Roussy ( Site 1202)

    Villejuif, Île-de-France Region, France

  • Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 2301)

    Budapest, Pest County, Hungary

  • Rambam MC ( Site 1500)

    Haifa, Israel

  • Hadassah Medical Center-Oncology ( Site 1504)

    Jerusalem, Israel

  • Rabin Medical Center ( Site 1502)

    Petah Tikva, Israel

  • Sheba Medical Center - Oncology Division ( Site 1501)

    Ramat Gan, Israel

  • Sourasky Medical Center ( Site 1503)

    Tel Aviv, Israel

  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 2402)

    Amsterdam, North Holland, Netherlands

  • Erasmus Medisch Centrum ( Site 2401)

    Rotterdam, South Holland, Netherlands

  • Auckland City Hospital ( Site 1700)

    Auckland, New Zealand

  • Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2201)

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.